Showing 1761-1770 of 2657 results for "".
- Eversight Names Diane Hollingsworth President/CEOhttps://modernod.com/news/eversight-names-diane-hollingsworth-president-ceo/2479171/Eversight announced that Diane Hollingsworth has been named President/CEO of the nonprofit eye bank network, effective immediately. Ms. Hollingsworth has served as interim President/CEO s
- Moderna Gives First Vaccine Shots To Young Kids As Part Of COVID-19 Studyhttps://modernod.com/news/moderna-gives-first-vaccine-shots-to-young-kids-as-part-of-covid-19-study/2478978/Children have now received their first doses of Moderna’s COVID-19 vaccine, as the company studies the safety and effectiveness of the vaccine for kids ages 6 months to less than 12 years old, according to an NPR
- Janssen Acquires Rights to Hemera Biosciences Investigational Gene Therapy for Late-Stage AMDhttps://modernod.com/news/janssen-acquires-rights-to-hemera-biosciences-investigational-gene-therapy-for-late-stage-amd/2478615/Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy. Financial terms of the transaction with
- Orbis International Announces Mary Jane Jamar as First Chief Human Resources Officerhttps://modernod.com/news/orbis-international-announces-mary-jane-jamar-as-first-chief-human-resources-officer/2478605/Orbis has named Mary Jane Jamar as the organization’s first Chief Human Resources Officer (CHRO). In this capacity, Ms. Jamar will also join and play a critical role on the Orbis Executive Leadership Team.
- PolyActiva Appoints Tracy Valorie to its Board of Directorshttps://modernod.com/news/polyactiva-appoints-tracy-valorie-to-its-board-of-directors/2478481/PolyActiva announced the appointment of experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors. Ms. Valorie is recognized in the industry for her success in building and leading high performing teams a
- Insurers Taking ‘Wait and See’ Approach to COVID-19 in 2021 ACA Exchange Rates: Expertshttps://modernod.com/news/insurers-taking-wait-and-see-approach-to-covid-19-in-2021-aca-exchange-rates-experts/2478454/Most insurers on the Affordable Care Act’s (ACA’s) insurance exchanges aren’t factoring COVID-19 into their 2021 rates or believe the pandemic will have a negligible effect, according to several experts, FierceHealthcare
- FDA Grants Orphan Drug Designation for Neurophth Therapeutics’ Gene Therapy for LHONhttps://modernod.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/Neurophth Therapeutics announced that its leading candidate, NR082, was granted an orphan drug designation (ODD) by the FDA for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) associated with ND4 mutation. LHON is a maternall
- 5 Reasons Why Medical Meetings Will Never Be the Samehttps://modernod.com/news/5-reasons-why-medical-meetings-will-never-be-the-same/2478276/In the wake of the COVID-19 pandemic, the virtual medical meeting is now the norm. And while it’s admirable that key data are being disseminated (often for free), there is no escaping the fact that it is a fundamentally different and lesser experience, according to commentary
- Orbis International Announces New CEO & Presidenthttps://modernod.com/news/orbis-international-announces-new-ceo-president/2478251/Orbis International announced the appointment of Derek Hodkey as the organization’s new CEO and President, with immediate effect, following the retirement of Bob Ranck, who led Orbis for over 4 years.
- ReVision Therapeutics Announces License With Cornell to Develop Treatment for Stargardt Diseasehttps://modernod.com/news/revision-therapeutics-announces-license-with-cornell-to-develop-treatment-for-stargardt-disease/2478230/ReVision Therapeutics announced that it has signed an exclusive license agreement with Cornell University for the development and commercialization of Cornell’s proprietary technology for the treatment of Stargardt disease, a genetic d